An In Silico Feasibility Study of Dose-Escalated Hypofractionated Proton Therapy for Rectal Cancer.

Cancers (Basel) · 2025 · PMC12384089 · PMID 40867256

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

The reduction in ID for PT may be significant for younger patients with a longer life expectancy, as there is evidence of a reduced risk of secondary cancer induction when using PT as compared to xRT [ 22 , 46 ].

also in 4,529 other papers

possibly significantno p-value reported

Planning studies have identified reduced doses to the bladder, femoral heads, and bowel bag as possibly significant advantages of PT over xRT [ 23 , 24 , 25 ] for rectal cancer.

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.